Waddell & Reed Financial’s Sarepta Therapeutics SRPT Stock Holding History

Waddell & Reed Financial’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	$12.6M	Sell	168,640 -941,262	-85%	-$86.9M	0.03%	391
2020 Q4	$189M	Sell	1,109,902 -19,088	-2%	-$2.83M	0.4%	61
2020 Q3	$159M	Sell	1,128,990 -2,443	-0.2%	-$371K	0.38%	60
2020 Q2	$181M	Sell	1,131,433 -870	-0.1%	-$118K	0.47%	51
2020 Q1	$111M	Sell	1,132,303 -3,668	-0.3%	-$419K	0.36%	75
2019 Q4	$147M	Sell	1,135,971 -51,155	-4%	-$5.16M	0.36%	68
2019 Q3	$89.4M	Buy	1,187,126 +131,544	+12%	+$15.5M	0.23%	124
2019 Q2	$160M	Buy	1,055,582 +723	+0.1%	+$87.9K	0.4%	65
2019 Q1	$126M	Sell	1,054,859 -129,286	-11%	-$16.6M	0.31%	85
2018 Q4	$129M	Buy	1,184,145 +240,510	+25%	+$30.1M	0.37%	64
2018 Q3	$152M	Buy	943,635 +159,235	+20%	+$21.8M	0.34%	83
2018 Q2	$104M	Buy	+784,400	New	+$74M	0.24%	119

Other funds holding SRPT

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Waddell & Reed Financial's SRPT Position: Q1 2021 in Review

Waddell & Reed Financial reduced its Sarepta Therapeutics (SRPT) stake by 85% in Q1 2021, selling an estimated $86.9M and leaving 168,640 shares worth $12.6M. The position accounts for 0.03% of the portfolio, ranked #391.

Waddell & Reed Financial first reported a position in SRPT in Q2 2018 and has held it in 12 quarters since. The position peaked at $189M in Q4 2020. 367 funds tracked by Wall St. Rank hold SRPT as of Q1 2021.

Waddell & Reed Financial held 168,640 shares of Sarepta Therapeutics worth $12.6M as of Q1 2021.
Waddell & Reed Financial sold 941,262 Sarepta Therapeutics shares in Q1 2021, an estimated $86.9M.
Sarepta Therapeutics made up 0.03% of Waddell & Reed Financial's portfolio in Q1 2021, its #391 holding.
Waddell & Reed Financial first reported a position in Sarepta Therapeutics in Q2 2018 and has held it in 12 quarters since.
Waddell & Reed Financial's Sarepta Therapeutics position peaked at $189M in Q4 2020.
367 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2021.

Based on Waddell & Reed Financial's 13F filing for Q1 2021, filed 12 May 2021.